Pharmaceutical

Haya secures $65m in Series A funds to advance heart failure treatment

Haya Therapeutics has secured $65m in Series A funding to expedite the clinical development of HTX-001 for treating heart failure.

May 10, 2025 - 06:00
Haya secures $65m in Series A funds to advance heart failure treatment
Haya Therapeutics has secured $65m in Series A funding to expedite the clinical development of HTX-001 for treating heart failure.
Read the original article

Tags:

Previous Article

FDA chief Martin Makary sets June deadline for genAI rollout

Next Article

Sanofi exec tells biotechs not to scrimp on clinical trial design

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

China’s NMPA grants conditional approval for AstraZeneca’s Calquence

China’s NMPA grants conditional approval for AstraZenec...

Mar 25, 2023

How bioconjugation is unlocking the next generation of drug development

How bioconjugation is unlocking the next generation of ...

Mar 29, 2025

STAT+: Health tech startups warn that overregulating AI could hamper innovation

STAT+: Health tech startups warn that overregulating AI...

Nov 23, 2023